Osteosarcoma

Bianchi, Gottardo; Gaiero, Leticia; Casales, Nicolas; Silveri, Claudio; Belzarena, Ana C.

doi:10.5772/intechopen.96765

Cited by 1 publication

(1 citation statement)

References 57 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No significant improvement in the treatment of osteosarcoma has been achieved in the past five decades. 15 However, recently, within the popularity of bioinformatics tools, prognostic models based on radiomic data or gene signatures combined with clinical features have emerged as powerful tools for precisely grouping patients with different prognoses and biological phenotypes; 10–12 these tools could be used to optimize the clinical management of patients and may therefore improve their outcomes.…”

Section: Discussionmentioning

confidence: 99%

A Novel Glutamine Metabolism-Related Gene Signature in Prognostic Prediction of Osteosarcoma

Lü¹,

Zhang²,

Liu³

et al. 2022

IJGM

View full text Add to dashboard Cite

Purpose Metabolic reprogramming, as one of the hallmarks of cancer, shows promising translational potential for cancer diagnosis, treatment and prognostic prediction. This study aims to construct and validate a prognostic prediction model for osteosarcoma based on glutamine metabolism-related genes. Materials and Methods A group of glutamine metabolism-related genes was identified from a public database and intersected with a list of osteosarcoma survival-related genes, and a risk score model based on sixteen glutamine metabolism-related genes was developed by using LASSO penalized Cox regression analysis. Results The prognosis of patients in the high-risk group was significantly worse than that of patients in the low-risk group in the training dataset (high- vs low-risk, 5-year overall survival: 11% vs 88%, p < 0.0001) and in two other external validation cohorts (high- vs low-risk, 5-year overall survival: 39% vs 81%, p = 0.015; 50% vs 94%, p = 0.011).In addition, a novel nomogram was constructed by integrating the risk score and clinical characteristics, including age, sex, metastasis status and chemotherapy response. This nomogram had superior predictive power compared with a nomogram composed of only conventional factors. Gene set enrichment analysis indicated that several well-known malignancy-associated gene sets, including MYC targets V1, DNA repair, and unfolded protein response, were enriched in the high-risk subgroup. Conclusion A novel glutamine metabolism-related prognostic prediction model and nomogram for osteosarcoma was developed and validated in the present study, which could predict the survival of patients with osteosarcoma and may facilitate individualized clinical decision-making for patients.

show abstract

Section: Discussionmentioning

confidence: 99%